Bio Screening Industry News

Archive for January, 2006

January 24, 2006

Pair of studies offer new clues to combat antibiotic resistance

Filed under: North America, Press Releases, HT Screening — admin @ 7:03 pm

In the continuing battle against antibiotic resistance, two new studies shed light on the complex defense mechanisms pathogenic bacteria use to evade antibiotic attack, an understanding of which could lead to new, more effective antibiotics to help save lives and combat the growing problem of antibiotic resistance. The studies, both of which target chemical components in the protective membrane surrounding bacterial cells, will appear in the February 17 inaugural print issue of ACS Chemical Biology, a new monthly publication of the American Chemical Society, the world�s largest scientific society.

In one study, researchers from the University of Michigan College of Pharmacy in Ann Arbor and the Borstel Research Center in Germany genetically engineered a strain of E. coli so that it lacks its normal outer protective layer of lipopolysaccharides, complex structures that help them defend against antibiotic attack. Removal of this layer is believed to make E. coli and other gram-negative bacteria more vulnerable to antibiotic attack, the scientists say.

“The study is further proof-of-principle that the spectrum of activity of antibiotics can be significantly extended by targeting the formation of lipopolysaccharides in the outer membrane,” says study co-author Timothy C. Meredith, Ph.D., a medicinal chemist who conducted the research as a doctoral student at the University of Michigan with Ron Woodard, Ph.D., a professor of medicinal chemistry at the university. Meredith is currently a researcher at Harvard Medical School in Boston.

Gram-negative bacteria, considered among the most virulent, include strains that are known to cause food borne illness, bubonic plague, Legionnaires� disease and cholera, among others. They are among the most difficult bugs to control using antibiotics, researchers say.

In another study published in the journal, researchers at Harvard Medical School and Harvard University built synthetic versions of natural substrates used by key enzymes to make teichoic acids, polymeric structures in the membrane surrounding gram-positive bacteria. The polymers are considered essential for bacterial survival. Until now, these enzyme precursors have been difficult to study due to their presence in low amounts, complexity and insolubility, says study leader Suzanne Walker, Ph.D., a professor in the Microbiology Department at Harvard Medical School.

The availability of synthetic precursors will make it easier to study how the gram-positive bacterial membrane is formed and aid in the design of new antibiotics to block its formation, says Walker. Her lab will soon begin screening for compounds that can block this important chemical pathway, she says.

Gram-positive bacteria include anthrax and other strains that cause upper respiratory infections and sepsis. In comparison to gram-negative bacteria, they are generally considered easier to control with antibiotics.

“Antibiotic resistance is a huge problem that is only going to get worse. We need new targets, especially if we�re going to circumvent resistance,” Walker says.

Both research teams caution that these new approaches may be years away from human testing and clinical use. Even if effective, bacteria can eventually develop ways to circumvent even the best laid approaches, underscoring the need for a better understanding of resistance machinery and the availability of new antibiotics, they say. Limited and selective use of antibiotics to prevent their overuse is also a way to stem resistance, according to health experts.

###

The American Chemical Society � the world�s largest scientific society � is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

EDITOR�S NOTE: For more information about ACS Chemical Biology, please visit http://pubs.acs.org/journals/acbcct/index.html

January 23, 2006

WuXi PharmaTech Appoints Angela Wong as Service Biology VP

Filed under: Asia, Press Releases, HT Screening — admin @ 5:49 pm

SHANGHAI, China, Jan. 23 /Xinhua-PRNewswire/ — WuXi PharmaTech Recently announced the key appointment of Dr. Angela Wong as Vice President of Service Biology.

Dr. Wong has board experiences in pharmacology, high throughput screening and preclinical pharmacokinetics. Prior to joining WuXi PharmaTech, she spent 20 years in pharmaceutical research at SmithKline, Pharmacopeia and Vitae Pharmaceuticals. She made significant contributions in multiple therapeutic areas including inflammation, cancer, hypertension, and osteoporosis. One of her compounds is currently in clinical trial for the treatment of asthma.

At her new post, Dr. Wong will be responsible for creating and managing Biology Service Group that provides services in the areas of drug metabolism, pharmacokinetics, toxicokinetics, immunoassay/biomarker, biological assay development and screening.

‘’I am very pleased to announce the appointment of such a highly accomplished professional to our management team. The addition of Dr. Wong to our scientific leadership broadens our service spectrum and enhances our capability. With her research experience and knowledge WuXi PharmaTech is one step closer to becoming an integrated R&D service provider,'’ WuXi PharmaTech’s Chairman & CEO Dr. Ge Li said.

Dr. Wong received her Bachelor of Science Degree in Biochemistry in 1977 and Master of Philosophy Degree in Biochemistry in 1980 from Chinese University of Hong Kong, and Ph.D. in Pharmacology from Baylor College of Medicine in Texas, United States.

Founded in 2001 and located in WaiGaoQiao Free Trade Zone, Shanghai, WuXi PharmaTech is a research service company that provides services to support new drug discovery and the chemical development of new drug candidates from discovery through to market. It engages in chemistry research, from lead discovery, optimization, bioanalytical services, and development to commercial manufacturing.

Wuxi PharmaTech assists its partners to shorten the cycle and lower the cost of drug development by providing complete, cost-effective and rapid chemistry solutions. The competent management team consists of many experienced ‘’returnees'’ and is well-versed in the latest drug R&D methodologies and Western style business practices. With over 650 scientists, the company has a 300,000 sq. ft. state-of-the-art research center and a 250,000 sq. ft. GMP plant. The company’s current customers include 18 of the top 20 pharmaceutical companies and 8 of the top 10 biopharmaceutical companies in the world.

For more information, please contact:

David Yin, PR Department,
WuXi PharmaTech Co., Ltd.
Tel: +86-21-5046-4003
Fax: +86-21-5046-1000
Email: Yin_Xiaojun@pharmatechs.com

Microneedle Drug Delivery Systems Hold Promise for Drug Developers; New Survey by Greystone Associates Examines Technology Advances and Market Potential

Advances in materials processing - technologies that include micromachining, nanoprocessing and structured film forming - are creating new devices and new opportunities for minimally invasive drug delivery. These advances have led to the development and introduction of devices that employ very small needles - microneedles - that deliver drugs by mechanically perforating the outer skin layer and allowing for transdermal absorption of the active compound. The processing techniques incorporate one or more technologies that enable the precise machining, extrusion, casting, and/or forming of from one to an array or grid of microneedles.

Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer a new class of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration.

“By penetrating the stratum corneum, microneedle delivery systems can effectively deliver drugs systemically with minimal discomfort,” explains George Perros, Greystone Associates Managing Director. “Evolving microneedle systems will be well-positioned to address a significant segment of the large-molecule biological drugs expected to emerge from the convergence of automated discovery and genome mapping.”

These findings are contained in a new and comprehensive report: Microneedle Drug Delivery: Technology, Markets, and Prospects. The survey concludes that microneedles and microneedle arrays will gain traction at the expense of injection and passive transdermal patches, particularly among emerging biologics.

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

CONTACT:

Greystone Associates Mark Smith, 603-595-4340 Fax: 603-804-0466 www.greystoneassociates.org

January 12, 2006

Agenda for first OncoProteomics World Congress Released

Filed under: North America, USA and Canada, Press Releases — admin @ 11:38 am

Select Biosciences are delighted to announce the inaugural World Congress dedicated to OncoProteomics will be held on the 27-28 April in South San Francisco. The top investigators applying proteomics to cancer research will be presenting their latest cutting edge work, providing a unique opportunity to delegates to network with the most senior researchers in the field.

Agenda sessions include:

- Alterations in the proteome in cancer

Keynote Speaker: Samir Hanash, Director, Fred Hutchinson Cancer Research Center

- Molecular diagnostics for cancer

Keynote Speaker: Gordon R. Whiteley, Director, Clinical Proteomics Reference Lab, NCI, Gaithersburg

- Protein biochips

Chaired by William E. Rich, CEO, Ciphergen

- Personalized therapies for cancer

Keynote Speaker: Jack A. Roth, Professor and Chairman, M. D. Anderson Cancer Center

For the full downloadable agenda (pdf) please visit www.OncoProteomicsCongress.com

Selected media partnerships are available for this event. For further information contact: Karen Saunders (ksaunders@selectbiosciences.com )

About Select Biosciences

www.SelectBiosciences.com

Select Biosciences Ltd. is focused on organizing specialist biomedical meetings. Experts from both academia and commerce present timely information from current research through to commercial implementation of new technologies.

Nanion Technologies GmbH hires Dr. Cecilia Farre to strengthen the ion channel expert team

Filed under: Europe, Press Releases — admin @ 10:57 am

After a successful introduction of Nanion’s first generation of automated patch clamp devices, the company seeks to expand its team and is very glad to hire Cecilia Farre, Ph.D., for research, product development as well as marketing and sales activities.

Dr. Cecilia Farre graduated in analytical chemistry and electrophysiology from Göteborg University, Sweden, where she also held a postdoctoral position in electrophysiology. Dr. Farre was employed as project manager and later on Vice President of Key Projects at Cellectricon AB, Göteborg, Sweden, where she played a key role in the development and commercialization of the company’s microfluidics platform.

“I am very impressed by Nanion´s automated patch clamp devices. The versatility of the products and their unprecedented ease-of-use offer a remedy to the bottlenecks of ion channel drug discovery as well as they facilitate novel experiments on ion channel function. I am happy and proud to join with Nanion Technologies.” says Dr. Farre.

Dr. Niels Fertig, CEO of Nanion Technologies, is very pleased about Dr. Farre’s joining the Nanion team: “We have successfully introduced our entry level device for automated patch clamp, the Port-a-Patch, which has been very well received by our customers. With the upcoming launch of our robotic multi-channel patch clamp workstation, the NPC-16, we want to strengthen our R&D team for customer support as well as our M&S for both the Port-a-Patch and the NPC-16. Dr. Cecilia Farre, with her strong background in ion channel screening instrumentation and commercialization, is a perfect fit to fill this position and we all welcome her on board!”

about Nanion:
Nanion Technologies (Germany) is a spin-off from the Center for Nanoscience (CeNS) of the University of Munich and is dedicated to providing flexible and customized solutions for ion channel research both in industry and academia. With the miniaturized Port-a-Patch©, Nanion offers the world’s smallest patch-clamp workstation. This innovative drug discovery technology makes patch clamp available also to non-electrophysiologists. The NPC©-16 additionally addresses the higher throughput requirements for ion channel screening and is a valuable tool for target validation and safety pharmacology (hERG screening).

For more information, please contact us at info@nanion.de or see also www.nanion.de

January 11, 2006

CytRx Announces Clinical and Corporate 2006 Milestones

Filed under: Business and Investment, HIV Research, Press Releases — admin @ 9:36 am

LOS ANGELES, Jan. 11 /PRNewswire-FirstCall/ — CytRx Corporation
(Nasdaq: CYTR) today announced projected major 2006 clinical and corporate
milestones and reviewed 2005 achievements aimed to advance the Company’s goal
to develop and commercialize human therapeutics, primarily in the area of
small molecules and ribonucleic acid interference (RNAi).

CytRx’s 2005 highlights include:

* 1Q05 — Completed enrollment in HIV DNA + protein vaccine Phase I
clinical trial

* 2Q05 — Received orphan drug status designation from the U.S. Food and
Drug Administration (FDA) for arimoclomol in the treatment of
amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease)

Filed an investigational new drug (IND) application with the
FDA for a Phase II clinical trial with arimoclomol for ALS
treatment

* 3Q05 — Announced interim positive data from HIV DNA + protein vaccine
Phase I clinical trial, indicating the first vaccine to
produce potent antibody responses with neutralizing activity
against multiple HIV viral strains

Commenced a Phase IIa clinical trial with arimoclomol for ALS

Granted “Fast Track” designation for arimoclomol for ALS

* 4Q05 — Entered into a significant licensing agreement with the
University of Massachusetts Medical School to develop newly
discovered obesity and type 2 diabetes drug targets

Major CytRx 2006 objectives:

* 1Q06 — Complete enrollment in Phase IIa clinical trial with
arimoclomol for ALS

* 2Q06 — Announce final results from a Phase I HIV DNA + protein
vaccine clinical trial

* 3Q06 — Report data from Phase IIa clinical trial with arimclomol for
ALS

Commence pivotal Phase IIb clinical trial following FDA review
and acceptance

CytRx also announced that it will continue to expand its program of small
molecule drug candidates against targets identified and validated using its
proprietary RNAi screening technology at its laboratory in Worcester,
Massachusetts. In addition, CytRx hopes to move a lead candidate from its
RNAi therapeutics drug development program, which focuses on type 2 diabetes,
obesity, cytomegalovirus and ALS, through the development phase toward an IND
submission.
“CytRx is in the enviable position of having numerous drug development and
discovery programs against novel drug targets in large market disease
indications, many of which have no effective treatments,” stated CytRx
President and CEO Steven A. Kriegsman. “Our plans for 2006 include actively
seeking large corporate partners to assist in the development of and
advancement toward commercialization of select drug candidates.
“We believe that creating awareness of the Company with the scientific and
investment communities is essential to advance CytRx and build substantial
increased value for our shareholders. To that end, we also plan to capitalize
on opportunities to present at scientific forums and investment conferences,”
he added.

About ALS
ALS is a progressive degeneration of the brain and spinal column nerve
cells that control the muscles that allow movement. According to the ALS
Survival Guide, 50% of ALS patients die within 18 months of diagnosis and 80%
die within five years. In the U.S., an estimated 30,000 people are living
with ALS and nearly 6,000 new cases are diagnosed annually, according to the
ALS Association. There are more than 120,000 people living with ALS
worldwide.

About Arimoclomol
The current Phase IIa clinical trial is a multi-center, double-blind,
placebo-controlled study of patients with ALS. Eighty ALS patients at 10
centers across the U.S. are included in the clinical trial. Patients will
receive either placebo (a capsule without drug), or one of three dose levels
of arimoclomol capsules three times daily, for a period of 12 weeks. The
primary endpoints of the Phase IIa trial are safety and tolerability.
Secondary endpoints include a preliminary evaluation of efficacy using two
widely accepted surrogate markers, the revised ALS Functional Rating Scale
(ALSFRS-R), which is used to determine a patient’s capacity and independence
in 13 functional activities, and Vital Capacity (VC), an assessment of lung
capacity.
The subsequent pivotal Phase IIb trial will be powered to detect more
subtle efficacy responses. Although this second trial is still in the
planning stages, it is expected to include 300 ALS patients recruited from 25
clinical sites and will take approximately 18 months to complete.

About HIV
HIV, the virus that leads to acquired immune deficiency syndrome (AIDS),
remains a global epidemic. World health officials estimate 40 million people
are now infected with HIV. Some 3 million people died of AIDS last year,
worldwide, and millions more are expected to die from AIDS this year. With
the rate of infection accelerating in many parts of the world, the search for
an effective HIV vaccine is one of the highest public health priorities.
Development of an HIV vaccine has been challenging because of the virus’
extraordinary degree of genetic diversity. HIV mutates rapidly in the
environment making it an elusive target for traditional vaccine strategies.

About DP6-001
The HIV DNA + protein vaccine formulation, which is exclusively licensed
to CytRx, was created by researchers at the University of Massachusetts
Medical School (UMMS) and Advanced BioScience Laboratories (ABL). This
program is funded under a $16 million five-year HIV Vaccine Design and
Development Team contract from the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of Health.
The HIV vaccine Phase I clinical trial was initiated in April 2004. The
goal of the Phase 1 clinical trial is to assess the ability of the vaccine to
safely stimulate both antibody and T-cell immune responses to viral protein
antigens in the vaccine, including “envelope,” which is also carried by HIV.
The envelope antigen is a critical protein on the surface of the AIDS virus
that facilitates the infection of humans. The vaccine initially “primes” the
subject’s immune system with injections of DNA that cause the subject’s own
cells to produce the HIV envelope proteins, followed by protein “boosts” from
an injection that contains the corresponding HIV envelope proteins. The
vaccine was tested in three groups of healthy volunteers: Group A received the
DNA vaccine under the skin, and Groups B and C received the DNA vaccine in
muscle, with Group C receiving a six-fold higher DNA dose compared with Groups
A and B. All were subsequently “boosted” with the mixture of envelope protein
antigen.

About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company
engaged in the development of products, primarily in the area of small
molecules and ribonucleic acid interference (RNAi). The Company owns three
clinical-stage compounds based on its small molecule “molecular chaperone”
co-induction technology, as well as 500 proprietary analogs with potential as
backups and new chemical entities (NCE) for new indications related to the
mechanism of chaperone co-induction. CytRx has initiated a Phase II clinical
trial with its lead small molecule product candidate arimoclomol for the
treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
Arimoclomol has received Orphan Drug and Fast Track designation from the U.S.
Food and Drug Administration. CytRx has previously announced that a novel HIV
DNA + protein vaccine exclusively licensed to CytRx and developed by
researchers at the University of Massachusetts Medical School (UMMS) and
Advanced BioScience Laboratories, and funded by the National Institutes of
Health, demonstrated very promising interim Phase I clinical trial results
that indicate its ability to produce potent antibody responses with
neutralizing activity against multiple HIV viral strains. For more
information, visit CytRx’s Web site at http://www.cytrx.com.

About Advanced BioScience Laboratories
Advanced BioScience Laboratories, Inc. (ABL) located in Kensington Md., is
a biomedical research, development and manufacturing company focusing on human
retroviral diseases. ABL has been a leader in HIV-1 research for more than
two decades and has been involved in the development of methods to both
prevent and treat HIV-1 infection.

About the University of Massachusetts Medical School
The University of Massachusetts Medical School, one of the fastest growing
academic health centers in the country, has built a reputation as a
world-class research institution, consistently producing noteworthy advances
in clinical and basic research. The Medical School attracts more than
$174 million in research funding annually, 80% of which comes from federal
funding sources. Research funding enables UMMS scientists to explore human
disease from the molecular level to large-scale clinical trials. Basic and
clinical research leads to new approaches for diagnosis, treatment and
prevention of disease. Visit http://www.umassmed.edu for additional information.

Forward-Looking Statements
This press release may contain forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Examples of such statements include, but are not limited to, statements
relating to the expected timing, scope and results of our clinical development
and research programs, including the initiation of clinical trials, and
statements regarding the potential benefits of our drug candidates and
potential drug candidates. Such statements involve risks and uncertainties
that could cause actual events or results to differ materially from the events
or results described in the forward-looking statements, including risks or
uncertainties related to regulatory approvals for clinical testing and the
scope of the clinical testing that may be required by regulatory authorities
for its molecular chaperone co-induction drug candidates, including
arimoclomol, and other products, and the timing and outcomes of those tests,
uncertainties related to the early stage of CytRx’s diabetes, obesity,
cytomegalovirus and ALS research, the need for future clinical testing of any
RNAi-based products and small molecules that may be developed by CytRx, the
significant time and expense that will be incurred in developing any of the
potential commercial applications for CytRx’s RNAi technology or small
molecules, CytRx’s need for additional capital to fund its ongoing working
capital needs, including ongoing research and development expenses related to
its molecular chaperone co-induction drug candidates, risks relating to the
enforceability of any patents covering CytRx’s products and to the possible
infringement of third party patents by those products, and the impact of third
party reimbursement policies on the use of and pricing for CytRx’s products.
Additional uncertainties and risks are described in CytRx’s most recently
filed SEC documents, such as its most recent annual report on Form 10-K, all
quarterly reports on Form 10-Q and any current reports on Form 8-K filed since
the date of the last Form 10-K. All forward-looking statements are based upon
information available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

For Additional Information:
CytRx Corporation: CEOcast, Inc.
Ed Umali (eumali@cytrx.com) Investor Contacts:
Director of Corporate Communications Kevin Theiss (ktheiss@ceocast.com)
(310) 826-5648, ext. 309 Cormac Glynn (cglynn@ceocast.com)
(212) 732-4300

Proteomic profiling to assess genetically modified crop safety

Filed under: Europe, Press Releases, Proteomics — admin @ 9:26 am

Wednesday, January 11, 2006
By Sirpa O. Kärenlampi and Satu J. Lehesranta

It is generally accepted that traditional food is safe for the majority of consumers. For the introduction of a new variant or cultivar developed from a traditional crop plant, maximum limits have been set in some cases, e.g., for potato and oilseed rape, to the content of known toxins.

The requirements are much more stringent if the crop is developed by using genetic engineering. Why is it so? In a majority of cases seen so far, a new gene, often derived from other plants or microbial species, has been introduced to a non-predetermined location in the plant genome. It is quite feasible to ask the question whether the new gene products are safe or not. Therefore, for all genetically modified crop plants, the safety of the newly introduced proteins needs to be demonstrated before the plants can be released into the market.

Another point of concern is the random integration of the new gene into the plant genome. Both the new gene itself and its site of integration may give rise to unintended adverse effects. For example, transgene integration might interrupt regulatory sequences or open reading frames leading to novel fusion proteins and, thereby, modify plant metabolism. These modifications could compromise the safety of the food crops by, for instance, leading to the production of new allergens or toxins. Having the gene and the integration site well characterised should provide a good basis for the safety assessment.

However, it is a common practice today to perform a large number of analyses, so-called targeted analyses, to demonstrate that the characteristics of the novel crop are comparable with those of the conventional counterpart, in addition to the intended alterations. Targeted analyses include key macronutrients, micronutrients, antinutrients, and toxins. In certain cases, toxicity studies on experimental animals are advised. And yet, the question about the unintended effects does not seem to be covered in a way that would escape all criticism.

Cellini et al. have considered transgene integration in the context of naturally occurring DNA recombination. It is well known that genetic variation is the cornerstone of plant breeding. Natural chromosomal recombination plays a central role in generating new variation. Non-homologous end joining, which is the predominant form of recombination in plants, rarely occurs without any sequence alterations, and usually gives rise to deletions of up to more than 1 kb and introduction of new filler DNA. Since the double-strand break repair system involved in recombination is more error-prone in plants than in other organisms, errors that change the original sequence occur at a very high frequency. The fact that gene-rich regions (and genes) are hotspots for recombination has facilitated the emergence of novel characteristics in crop plants.

Integration of exogenous DNA (transgene) occurs via the same mechanism as natural recombination. Several types of rearrangements are thus observed, both in transgene integration sites and in natural recombination sites. While this mechanism provides a selection of natural variation for breeders, it is also a source of unintended effects similar to that in genetically engineered crop plants.

In the light of variation generated by natural recombination and by the repertoire of conventional breeding technologies exploited for decades, the question is how much variation in the overall genetic makeup of a crop plant might be generated by the transfer and integration of a single gene, compared to the variation already existing. A related question is how probable are the unintended effects that extend beyond this variation.

To answer these and other questions, we made a comparative analysis of eight GM lines of potato, including vector-only lines without the target gene. The parent cultivar, Desirée, and a line that had undergone tissue culture only, were included as non-GM comparators. Nine of 730 proteins showed statistically significant differences among the GM lines and controls. No new proteins that would be unique to the individual GM lines were observed. The conclusion from this study, supported by the EU-funded GMOCARE project, was that there was no evidence for any major changes in protein patterns of the GM lines tested.

It can be argued that proteomics is not sensitive enough to find differences between potato lines or varieties. The European breeders have developed a large number of very different potato cultivars, many of them with genes introgressed from other Solanum species. Of that diversity, we analysed 32 non-GM potato genotypes, including 21 conventional cultivars, eight landraces, and three lines of S. phureja. From that study it was obvious that there is a great deal of variation in the protein patterns of the different potato genotypes: out of 1111 protein spots analyzed, 1077 differed significantly among two or more genotypes. The protein profile of the diploid species S. phureja could be clearly distinguished from the ones of the tetraploid S. tuberosum genotypes.

These studies indicated that the variation between the non-GM cultivars/genotypes was much greater than the differences between the GM lines. This was further confirmed by direct comparison of some of the GM lines with two non-GM genotypes; there was no separation among the GM lines and their control, but the two non-GM genotypes separated very clearly from each other and from all Desirée-based lines. In other words, there were considerably fewer differences between the GM and non-GM lines of the same genetic background than between different non-GM cultivars. Many of the proteins that contributed to the separation of the non-GM genotypes appeared to be involved in disease and defense responses, sugar and energy metabolism, or protein targeting and storage, and are presently considered to convey no safety risk.

Our results have been corroborated recently by Catchpole et al., who compared several GM potato lines and cultivars using metabolic profiling. The authors found differences between the GM lines only in those metabolites that were targets of the genetic modification; apart from those compounds, the GM lines could not be distinguished from their controls. On the other hand, all cultivars could be clearly distinguished from one another.

The results of both profiling studies are not surprising, considering what is now known about the nature of plant genome and its dynamics. Even though genetic modification does not generate major changes apart from the ones targeted, a protein identified at an increased level in the GM line compared to the conventional counterpart might be worth further attention if the level clearly falls outside the normal variation. This is to exclude any risks from, for example, potent allergens. As current profiling methods produce a huge amount of data, it is almost inevitable that some statistically significant differences will be found. Therefore the focus should be in truly consistent differences.

How feasible are profiling techniques in general as tools to provide additional data for the risk assessment of GM crops? Do they provide added value worth the investment? Do they give reassurance that unintended adverse effects have not occurred? Non-targeted methods, such as transcriptional, protein, and metabolite profiling, offer potentially unbiased approaches to the detection of unintended effects. Of these, transcriptomics is possibly the most comprehensive, with full genome arrays currently available for a limited number of plant species.

While it is clear that a comprehensive coverage of all proteins and metabolites present in a given tissue is difficult to obtain with current technologies, proteins are the key molecules of interest, as they are potential allergens and catalyse the synthesis of metabolites, some of which are potential toxins.

To assess observed differences within the context of natural variation in composition, comparative data of ‘normal’ protein levels are needed to understand the effect of genetic background, developmental stages, physiological states, environmental conditions, and cultivation techniques, and to be able to set the criteria against which a determination of a significant difference worth considering as a possible safety risk can be made. Currently there is very little information publicly available on protein patterns in potato tubers or in any other crops.

As with other profiling methods, proteomic screening is not yet routine for assessing the safety of GM products. However, proteomic profiling has the potential to reduce uncertainty by providing much more information about crop composition than does targeted analysis alone, especially in combination with other profiling methods. In addition, multivariate statistical methods can give a much better overall picture of how the given samples relate to each other than does the comparison of single compounds. These facts may make proteomics increasingly important when developing second generation GM crops with multiple genes, engineered metabolic pathways, or edible pharmaceuticals.

References:

Kuiper HA, Kleter GA, Noteborn HPJM & Kok EJ (2001) Assessment of the food safety issues related to genetically modified foods. Plant J 27, 503-528

Cellini F et al. (2004) Unintended effects and their detection in genetically modified crops. Food Chem Toxicol 42, 1089-1125

Lehesranta SJ, Davies HV, Shepherd LVT, Nunan N, McNicol JW, Auriola S, Koistinen KM, Suomalainen S, Kokko HI, & Kärenlampi SO (2005) Comparison of tuber proteomes of potato (Solanum sp.) varieties, landraces and genetically modified lines. Plant Physiol 138, 1690-1699

Catchpole GS, Beckmann M, Enot DP, Mondhe M, Zywicki B, Taylor J, Hardy N, Smith A, King RD, Kell DB, Fiehn O & Draper J (2005) Hierarchical metabolomics demonstrates substantial compositional similarity between genetically modified and conventional potato crops. Proc Natl Acad Sci USA 102, 14458-14462

Sirpa O. Kärenlampi and Satu J. Lehesranta
Institute of Applied Biotechnology, University of Kuopio
FIN-70211 Kuopio, Finland
skarenla@messi.uku.fi

New Release Genedata Screener Improves Strategy for High Throughput Screening Analysis

Filed under: Europe, ChemInformatics, Press Releases, HT Screening — admin @ 9:21 am

BASEL, Switzerland, January 11 2006 - Genedata announces the release of Genedata Screener® 4.0, an open and scalable solution for high throughout screening (HTS) analysis. The software now boasts a well documented public application programming interface (API) and advanced procedures for analyzing high content screening data.

“We’ve created a powerful and straightforward strategy for validating data quality and pinpointing the most promising lead compounds”, says Dr. Michael Lindemann, Business Head Genedata Screener. The software handles high content screening data and consolidates Screener’s strengths in compound potency measurement using dose-response curve fitting.

New features include an API to link Screener’s database resources with the client’s existing corporate information portals. The release has new sorting and filtering capabilities that have been specially developed for lead discovery and compound validation.

“Screener 4.0 addresses recent moves in HTS towards cellular systems, biomolecular aspects of ADMET, and functional genomics”, explained Dr. Stephan Heyse, Project Head Genedata Screener. Genedata has honed its competencies in high content screening data analysis. It recently issued a joint statement with Evotec Technologies describing a high throughput solution for imaging screens. These features have been integrated into the 4.0 release.

Screener’s open architecture facilitates tight IT integration without costly customization. Dr. Lindemann added, “Our technologies bring benefit to focused screening campaigns in specific therapeutic areas as well as large scale screening operations”.

Contact Genedata

Dr. Tobe Freeman
Manager Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com

About Genedata Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia)

Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Plant Compounds Inhibit Blood Clotting

Filed under: North America, Natural Products — admin @ 9:17 am

After screening hundreds of phytochemicals found in a variety of plants, an ARS scientist has identified, characterized, and synthesized two potentially heart-healthy natural compounds.

These compounds, either in foods or as dietary supplements, may be important for alleviating the symptoms of heart disease related to blood clots. Rigorous testing and regulatory approval is prerequisite.

The research was conducted by ARS biochemist Jae B. Park at the Beltsville ( Maryland) Human Nutrition Research Center’s Phytonutrients Laboratory. Park presented the findings at the 2005 annual meeting of the Federation of American Societies for Experimental Biology, in San Diego, California. The chemical structures of the compounds and their biological activities were filed in a 2005 patent application.

The natural compounds that were synthesized are N-caffeoyldopamine and N-coumaroyldopamine, and their analogs, which are found in sweet peppers, Chinese wolfberry, and cocoa. When tested in larger quantities than likely found in foods, these compounds suppress the mechanism whereby blood platelets stick to blood vessel walls.

Platelets play an important role in blood clotting. They release chemicals that cause the cascade of events that form plugs at the site of injury within blood vessel walls.

Park found that the compounds significantly suppress an adhesive molecule, P-selectin, that glues platelets to white blood cells and blood vessel walls. White blood cells, or leukocytes, move through vessel walls to damaged areas, where they surround and isolate dead tissue and foreign bodies and also produce antibodies.

During the aging process, fatty substances in blood plasma can accumulate inside blood vessel walls. These fat deposits trigger cells to release molecules that cause a chain of events in which immune cells, proteins, and calcium in the bloodstream also adhere to the blood vessel’s inner wall. All these substances combine to form plaque.

Plaque buildup can obstruct arteries and lead to blood clotting. “Blood clotting causes the artery to narrow even more, and in some cases, prevents the blood from supplying the heart muscle, which results in a condition called ¡®acute coronary syndrome,” says Park.

To test the biological activities of the compounds, Park collected blood from mice and exposed it to the compounds. He then studied the compounds’ effects on P-selectin expression and platelet-leukocyte interactions.

“The compounds were found to be potent in their ability to inhibit chemical reactions that lead to blood clotting, such as platelet activation and platelet-leukocyte interaction,” says Park.

While it’s long been known that plant chemicals promote health, they have not been measured in foods to the extent that the essential vitamins have. Therefore, it is unknown whether the quantity of the newly studied compounds normally present in foods is enough to elicit the suppression response. Park is now measuring the compounds in plant sources using newly developed analytical methods. - By Rosalie Marion Bliss, Agricultural Research Service Information Staff.

This research is part of Human Nutrition, an ARS National Program (#107) described on the World Wide Web at www.nps.ars.usda.gov.

Jae B. Park is with the USDA-ARS Phytonutrients Laboratory, 10300 Baltimore Ave., Bldg. 307-C, Room 133, Beltsville, MD 20705; phone (301) 504-8365, fax (301) 504-9456.

Source: ARS USDA

January 6, 2006

Athersys Extends Partnership With Bristol-Myers Squibb To Provide Drug Targets

Filed under: North America, Collaborations, Press Releases — admin @ 11:18 am

CLEVELAND, Jan. 6 /PRNewswire/ — Athersys Inc. announced today that it
has extended its existing alliance with Bristol-Myers Squibb Company
(NYSE: BMY) to apply its patented RAGE technology to provide Bristol-Myers
Squibb with additional validated drug targets for high-throughput screening
and lead optimization in multiple therapeutic areas. The new agreement will
extend the alliance for up to three years with a guaranteed minimum number of
targets to be supplied by Athersys annually. Under the terms of the
extension, Athersys is entitled to receive license fees for targets delivered
to Bristol-Myers Squibb, as well as milestone payments and royalties on
compounds developed by Bristol-Myers Squibb using the Athersys technology.
The collaboration extension builds upon an on-going partnership and two
previous agreements between the companies. Athersys and Bristol-Myers Squibb
originally entered into a research and development collaboration in January
2001 and then expanded the collaboration in July 2002. Over the course of the
partnership, Athersys has successfully delivered multiple drug targets to
Bristol-Myers Squibb from distinct target classes and in a variety of
therapeutic areas. These targets provide the foundation for several active
drug development programs at Bristol-Myers Squibb. As part of the extended
partnership, the companies will continue to work closely together to
facilitate certain drug development activities at Bristol-Myers Squibb.
“Athersys is delighted to continue our long-standing partnership with
Bristol-Myers Squibb,” said John Harrington, Ph.D., Executive Vice President
and Chief Scientific Officer of Athersys. “During the past several years,
Athersys has continued to refine its proprietary technologies and provide our
partners with access to important validated drug targets. This collaboration
extension represents an important financial transaction for the company, and
provides further validation for the technological foundation of our internal
drug development programs.”

About RAGE
RAGE (Random Activation of Gene Expression) is a novel gene expression
system developed by Athersys scientists that provides the unique ability to
produce protein from virtually any gene in the human genome, without requiring
the cloning of individual genes or use of cDNA libraries. The technology may
be used to facilitate the mapping of complex biological pathways using genome-
wide protein expression libraries produced using RAGE in conjunction with cell
based assays, or may be used as a means to produce cell lines that express
individual drug targets of interest.

About Athersys
Athersys is a biopharmaceutical company engaged in the development and
commercialization of therapeutic products to treat significant and life-
threatening diseases. The company has three primary focus areas, which
include: regenerative medicine (applying the MultiStem(TM) cell therapy
platform); medicinal chemistry & pharmacology; and functional genomics
(applying the company’s RAGE & GECKO technologies). In addition to its cell
therapy programs applying MultiStem(TM) toward the treatment of cardiovascular
disease, stroke, oncology support and certain other diseases, Athersys
currently has active drug development programs for obesity, cognition
enhancement and asthma. Athersys’ RAGE and GECKO (Genome-wide Cell-based
Knockout(TM)) technologies have powerful applications in the area of
functional genomics, such as the generation of cell lines expressing validated
drug targets and the identification of cellular differentiation factors.
Athersys is a founding member of the Center for Stem Cell and Regenerative
Medicine (CSCRM) based in Cleveland, Ohio. CSCRM is a non-profit multi-
institutional collaborative initiative established by the Cleveland Clinic,
University Hospitals, Case Western Reserve University, the Ohio State
University and Athersys that is focused on accelerating translational research
applying advanced stem cell and regenerative medicine technologies. This
press release and further information on Athersys, Inc. can be found on the
World Wide Web at: http://www.athersys.com.
For Athersys: Statements herein that are not descriptions of historical
facts are forward-looking and subject to risk and uncertainties. Actual
results could differ materially from those currently anticipated due to a
number of factors, including risks relating to the early stage of products
under development; uncertainties relating to clinical trials; dependence on
third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company’s proposed products (such as
marketing, safety, regulatory, patent or product liability, supply,
competition and other risks).

Next Page »

Powered by WordPress